The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial
Abstract
IMPORTANCE: Children born prematurely who develop retinopathy of prematurity (ROP) often develop myopia, and those who require laser treatment may develop very high myopia, which has considerable clinical consequences. OBJECTIVE: To report refractive outcomes in preterm infants who developed ROP in zone I or zone II posterior as stage 3+ ROP or aggressive posterior ROP (APROP). DESIGN, SETTING, AND PARTICIPANTS: All infants received intravitreal bevacizumab or laser therapy in a prospective, stratified, randomized, controlled, masked, multicenter clinical trial, Bevacizumab Eliminates the Angiogenic Threat for ROP (BEAT-ROP). Children who received intravitreal bevacizumab or laser in the BEAT-ROP clinical trial, with treatment randomized by infant, underwent cycloplegic retinoscopic refraction at a mean age of 2½ years. Fifteen centers with both pediatric and vitreoretinal ophthalmologists participating in level 3 neonatal intensive care units in academic centers with institutional review board approval were included in the trial. Of the originally enrolled 150 infants (300 eyes) in the BEAT-ROP clinical trial, 13 infants (26 eyes) died (6 received intravitreal bevacizumab; 7 received laser) and 19 eyes had intraocular surgery (6 infants bilaterally). Thus, 45 eyes (19 infants bilaterally) were excluded, leaving 131 infants (255 eyes, including 21 eyes that received a successful second treatment for recurrence). INTERVENTIONS: Follow-up of the BEAT-ROP cohort. MAIN OUTCOMES AND MEASURES: Spherical equivalent refractive outcomes and their distribution by ROP zone and treatment. RESULTS: Refractions were available for 109 of 131 eligible infants (83.2%) and 211 of 255 eyes (82.7%). Mean (SD) spherical equivalent refractions were as follows: zone I, -1.51 (3.42) diopters (D) in 52 eyes that received intravitreal bevacizumab and -8.44 (7.57) D in 35 eyes that received laser treatment (P < .001); and zone II posterior, -0.58 (2.53) D in 58 eyes that received intravitreal bevacizumab and -5.83 (5.87) D in 66 eyes that received laser treatment (P < .001). Very high myopia (≥-8.00 D) occurred in zone I in 2 of 52 (3.8%) eyes that received intravitreal bevacizumab and in 18 of 35 (51.4%) eyes that received laser treatment (P < .001). Very high myopia occurred in zone II posterior in 1 of 58 (1.7%) eyes that received intravitreal bevacizumab and in 24 of 66 (36.4%) eyes that received laser treatment (P < .001). CONCLUSIONS AND RELEVANCE: More very high myopia was found in eyes that received laser treatment than in eyes that received intravitreal bevacizumab. This difference is possibly related to anterior segment development that is present with intravitreal bevacizumab but minimal or absent following laser treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00622726.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Retinopathy of Prematurity Revisited
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.991 · Cited by 2,932
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
Mintz-Hittner, H. A., Kennedy, K. A., & Chuang, A. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007374 · Cited by 1,455
Self-citationGole, G. A., Ells, A. L., Katz, X., Holmström, G. E., Fielder, A. R., Capone, A., Flynn, J. T., Good, W., Holmes, J. M., McNamara, J. A., et al. (2005) · Archives of Ophthalmology · Cited by 1,386
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.12.1769 · Cited by 1,001
Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Preliminary Results
Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) · Pediatrics · doi:10.1542/peds.81.5.697 · Cited by 503
O’Connor, A. R., Stephenson, T., Johnson, A., Tobin, M. J., Moseley, M. J., Ratib, S., Ng, Y., & Fielder, A. R. (2002) · Pediatrics · doi:10.1542/peds.109.1.12 · Cited by 283
Holmström, G., & Larsson, E. K. B. (2007) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2007.08.012 · Cited by 100
Postnatal Retinal Vascularization in Former Preterm Infants with Retinopathy of Prematurity
Mintz-Hittner, H. A., & Kretzer, F. L. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31301-7 · Cited by 32
Self-citation
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Screening Examination of Premature Infants for Retinopathy of Prematurity
Fierson, W. M., AMERICAN ACADEMY OF PEDIATRICS Section on Ophthalmology, AMERICAN ACADEMY OF OPHTHALMOLOGY, AMERICAN ASSOCIATION FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, AMERICAN ASSOCIATION OF CERTIFIED ORTHOPTISTS, Chiang, M. F., Good, W., Phelps, D., Reynolds, J., Robbins, S. L., et al. (2018) · Pediatrics · doi:10.1542/peds.2018-3061 · Cited by 1,460
Metadata
- Authors
- Geloneck, M. M., Chuang, A. Z., Clark, W. L., Hunt, M. G., Norman, A. A., Packwood, E. A., Tawansy, K. A., & Mintz-Hittner, H. A.
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-11-01
- Volume
- 132
- Issue
- 11
- Pages
- 1327
- ISSN
- 2168-6165 (ISSN-L)
- OpenAlex
- W2101535867
- Cited by
- 327
- References
- 8
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaophthalmol.2014.2772
- The paper
- Geloneck, M. M., Chuang, A. Z., Clark, W. L., Hunt, M. G., Norman, A. A., Packwood, E. A., Tawansy, K. A., & Mintz-Hittner, H. A. (2014). Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial. JAMA Ophthalmology. https://doi.org/10.1001/jamaophthalmol.2014.2772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.